TY - DATA T1 - Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli PY - 2016/07/04 AU - Benjamin J. Ereshefsky AU - Majdi N. Al-Hasan AU - Yevgeniya Gokun AU - Craig A. Martin UR - https://tandf.figshare.com/articles/journal_contribution/Comparison_of_-lactam_plus_aminoglycoside_versus_-lactam_plus_fluoroquinolone_empirical_therapy_in_serious_nosocomial_infections_due_to_Gram-negative_bacilli/3470516 DO - 10.6084/m9.figshare.3470516.v1 L4 - https://ndownloader.figshare.com/files/5464454 KW - Combination therapy KW - Nosocomial infection KW - Antibiotic therapy KW - Pneumonia KW - Bacteremia KW - Gram-negative bacilli N2 - We sought to compare clinical cure on day 7 and a 28-day all-cause mortality in patients who received an anti-pseudomonal ß-lactam with a fluoroquinolone or an aminoglycoside for treatment of nosocomial bacteremia or pneumonia due to Gram-negative bacilli while in the ICU. This retrospective cohort study was conducted in critically ill patients at an academic medical centre from January 2005 to August 2011. A total of 129 patients (83 receiving aminoglycoside and 46 receiving fluoroquinolone combinations) were included. Seven-day clinical cure rates were 74% and 72% for fluoroquinolone and aminoglycoside groups, respectively (p = 0.84). There was no significant difference in the odds of clinical cure with a fluoroquinolone as compared to an aminoglycoside combination (adjusted odds ratio 2.4, 95% confidence interval [CI] 0.7–9.0). There was no significant difference in 28-day mortality in patients who received a fluoroquinolone or an aminoglycoside combination (22% vs. 18%, adjusted hazard ratio 0.82, 95% CI 0.29–2.28). ER -